| 臺大學術典藏 |
2021-09-01T02:02:40Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:37Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
ANN-LII CHENG; Yeh K.-H.; Lin J.-T.; Hsu C.; Liu M.-Y. |
| 臺大學術典藏 |
2021-09-01T02:02:32Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Liu H.-T.; Hsu C.; Chen C.-L.; Chiang I.-P.; Chen L.-T.; Chen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Hsu C.; Chen C.-L.; Chen L.-T.; Liu H.-T.; Chen Y.-C.; Jan C.-M.; Liu C.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Hsu C.; Huang C.-L.; Hsu H.-C.; Lee P.-H.; Wang S.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-09-01T02:02:26Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; ANN-LII CHENG; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:25Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Hsu C.; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:23Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Hsu C.; Wang J.-D.; Hwang J.-S.; Tien H.-F.; Chang S.-M.; ANN-LII CHENG; Chen Y.-C.; Tang J.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:22Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; Lee P.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Shen Y.-C.; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:20Z |
Recent advances in non-surgical treatment for advanced hepatocellular carcinoma
|
Hsu C.; Cheng J.C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:19Z |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
|
Shen Y.-C.; Hsu C.; Chen J.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:18Z |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:18Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.; Yang C.-H.; Yu C.-J.; Hsu C.; ANN-LII CHENG; Yang P.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:16Z |
Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis
|
Shen Y.-C.; Chang C.-J.; Hsu C.; Cheng C.-C.; Chiu C.-F.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:13Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T02:02:13Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; ANN-LII CHENG; Hsu C.; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis
|
Hsu C.; Shen Y.-C.; Cheng C.-C.; Hong R.-L.; Chang C.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:07Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:31Z |
Molecular targeted therapy for advanced hepatocellular carcinoma
|
Shen Y.C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:30Z |
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
|
Hsu C.; Hsiung C.A.; Su I.-J.; Hwang W.-S.; Wang M.-C.; Lin S.-F.; Lin T.-H.; Hsiao H.-H.; Young J.-H.; Chang M.-C.; Liao Y.-M.; Li C.-C.; Wu H.-B.; Tien H.-F.; Chao T.-Y.; Liu T.-W.; ANN-LII CHENG; Chen P.-J. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
|
Hsu C.; Wei S.-C.; ANN-LII CHENG; Chen P.-J. |
| 臺大學術典藏 |
2021-09-01T01:54:23Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:23Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:22Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Hsu C.; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:20Z |
Lamivudine and hepatitis B reactivation
|
Hsu C.; ANN-LII CHENG; Chen P.-J. |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
|
Hsu C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:18Z |
Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
|
Hsu C.; Shen Y.-C.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives
|
Shen Y.-C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:15Z |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Shen Y.-C.; Hsu C.; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:14Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.; ANN-LII CHENG; Hsu C.; Chen C.-M. |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.; Shen Y.-C.; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
Hsu C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
